Spinogenix, Inc.

Spinogenix, Inc. is a clinical-stage biopharmaceutical company founded in 2016, headquartered in Los Angeles, California. The company is dedicated to pioneering first-in-class therapeutics aimed at restoring brain synapses to address the unmet medical needs of patients suffering from neurodegenerative, neuropsychiatric, and neurodevelopmental conditions worldwide.

Spinogenix focuses on developing novel small molecules designed to regenerate and correct synaptic function. Its lead drug candidates include Tazbentetol (formerly SPG302), an oral small molecule engineered to regrow brain synapses, currently being evaluated for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, and schizophrenia. The company is also advancing SPG601, another oral small molecule, which aims to normalize brain abnormalities in Fragile X Syndrome (FXS). Both Tazbentetol and SPG601 have received Orphan Drug Designation from regulatory bodies, with SPG601 also holding FDA Fast Track Designation for FXS.

Under the leadership of founder and CEO Dr. Stella Sarraf, Spinogenix has reported significant clinical progress. In December 2025, the company announced positive Phase 2a results for Tazbentetol in Alzheimer's disease, demonstrating improvements in memory and thinking, and in November 2025, positive Phase 2a results for SPG302 in ALS, indicating a potential to slow disease progression. In April 2026, Spinogenix initiated a Phase 2b/3 trial for SPG601 in Fragile X Syndrome and reported early improvements in a Phase 2 trial for Tazbentetol in schizophrenia in March 2026. The company operates as a privately held entity, having secured funding through multiple rounds and grants, including support from the U.S. Department of Defense.